Chalcogen Hetero Ring Attached Directly Or Indirectly To The Piperazine Ring By Nonionic Bonding Patents (Class 514/254.07)
  • Publication number: 20120178762
    Abstract: The present invention is directed to solvates and various polymorphic forms of (E)-1-[[[5-(4-chlorophenyl)-2-furanyl]methylene]amino]-3-[4-(4-methyl-1-piperazinyl)butyl]-2,4-imidazolidinedione dihydrochloride and pharmaceutical compositions thereof.
    Type: Application
    Filed: February 3, 2012
    Publication date: July 12, 2012
    Applicant: WARNER CHILCOTT COMPANY, LLC
    Inventors: Nancy Lee REDMAN-FUREY, Nicholas William GEARY, Tammy BAKER
  • Publication number: 20120177712
    Abstract: This invention relates to a bipolar antimicrobial particle for use in laundry detergent compositions, fabric conditioners, personal care and cosmetic compositions and a process for making the same. In view of the foregoing, it is an object of the present invention to provide a stabile antimicrobial agent immobilised on a carrier particle. It is a further objective to provide an antimicrobial particle with improved retention to the fabric so that larger amounts of antimicrobial will be available even after rinsing. Surprisingly it has been found that antimicrobial molecules tagged by surface reaction onto naturally occurring asymmetric clay surfaces, act as an antimicrobial particle with improved retention properties with improved stability.
    Type: Application
    Filed: August 30, 2010
    Publication date: July 12, 2012
    Inventors: Arpita Bhattacharya, Sudipta Ghosh Dastidar, Vidula Iyer, Suresh Sambamurthy Jayaraman, Maya Treesa Saji
  • Publication number: 20120178724
    Abstract: In accordance with the present invention, novel methods and formulations are provided for treating and preventing the incidence of drug-induced pro-arrhythmia, including torsades de pointes. The methods and formulations comprise a combination of a drug that induces torsade de pointes, such as Class III antiarrhythmics, certain antimicrobials, antihistamines, antidepressants, antipsychotics, diuretics, with an aspirin and/or a statin. In certain embodiments, the compositions and methods for treatment comprise azimilide and aspirin and/or a statin. These compositions may be administered by different routes, including orally. In certain embodiments where the antiarrhythmic is azimilide it may be administered orally in a dose of about 25 mg to about 300 mg.
    Type: Application
    Filed: March 22, 2012
    Publication date: July 12, 2012
    Applicant: WARNER CHILCOTT COMPANY, LLC
    Inventors: Joseph Michael Sprafka, II, Jose Mauro Goulart-Brum
  • Publication number: 20120172364
    Abstract: Rate-controlled particles, comprising compounds of the formula as a solid dispersion.
    Type: Application
    Filed: March 14, 2012
    Publication date: July 5, 2012
    Inventors: Thomas Hantke, Bettina Rehbock, Jörg Rosenberg, Jörg Breitenbach
  • Publication number: 20120157396
    Abstract: Applicants claim the use of a pyrazine compound of formula I: or a salt thereof, for treating or preventing leishmaniases, and diseases and disorders caused by Trypanosoma cruzi or Trypanosoma brucei, and for inducing immunostimulation.
    Type: Application
    Filed: November 21, 2011
    Publication date: June 21, 2012
    Applicants: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, UNITED STATES GOVERMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIR, CORNELL UNIVERSITY
    Inventors: John T. WELCH, Susana MENDEZ, Michael H. CYNAMON
  • Publication number: 20120129844
    Abstract: There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.
    Type: Application
    Filed: January 26, 2012
    Publication date: May 24, 2012
    Inventors: David Buttar, Kevin Michael Foote, Maria-Elena Theoclitou, Andrew Peter Thomas
  • Publication number: 20120114600
    Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: November 3, 2011
    Publication date: May 10, 2012
    Applicant: THERAVANCE, INC.
    Inventors: Robert Murray McKINNELL, Daniel D. LONG, Lori Jean VAN ORDEN, Lan JIANG, Mandy LOO, Daisuke Roland SAITO, Shella ZIPFEL, Eric L. Stangeland, Kassandra Lepack, Gavin Ogawa
  • Publication number: 20120114604
    Abstract: The present invention relates to co-administering a Hepatitis C virus NS3/4A protease inhibitor and a cytochrome P450 monooxygenase inhibitor. The combination acts by interfering with the life cycle of the hepatitis C virus and is therefore useful as an antiviral therapy. As such, the combination may be used for treating or preventing Hepatitis C infections in patients. The invention also relates to compositions comprising the combination of inhibitors. The invention also relates to kits and pharmaceutical packs comprising a Hepatitis C virus NS3/4A protease inhibitor and a cytochrome P450 monooxygenase inhibitor. The invention also relates to processes for preparing these compositions, combinations, kits, and packs.
    Type: Application
    Filed: January 23, 2012
    Publication date: May 10, 2012
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Roger Tung, Gurudatt Chandorkar, Robert Perni
  • Publication number: 20120115881
    Abstract: A novel arylpiperazine-containing imidazole 4-carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating a depressive disorder are provided.
    Type: Application
    Filed: July 9, 2010
    Publication date: May 10, 2012
    Applicant: GREEN CROSS CORPORATION
    Inventors: Jinhwa Lee, Hee Jeong Seo, Suk Youn Kang, Eun-Jung Park, Min Ju Kim, Suk Ho Lee, Jong yup Kim, Jeongmin Kim, Myung Eun Jung, Hyun Jung Kim, Mi-soon Kim, Ho kyun Han, Kwang Woo Ahn, Min Woo Lee, Ki-Nam Lee, Ae Nim Pae, Woo-Kyu Park
  • Publication number: 20120114574
    Abstract: Novel topical compositions for the treatment of nail and skin afflictions comprising at least one active agent, at least one volatile solvent, at least one film-forming ingredient and at least one phospholipid, processes for their preparation and methods of treatment of nail and skin afflictions. Following application of the compositions and evaporation of volatile solvents, the composition produces a film, which has web-like structures containing the active agent(s).
    Type: Application
    Filed: August 1, 2011
    Publication date: May 10, 2012
    Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventor: Elka Touitou
  • Publication number: 20120101053
    Abstract: The present invention relates to compounds capable of inhibiting and/or decreasing the activity of one or more cathepsins, thereby treating and/or preventing various disease states associated with one or more cysteine proteases including, but not limited to, cathepsins and papain-like cysteine proteases. Disease states treated and/or prevented by the compounds of the invention include, but are not limited to, mammalian parasitic diseases in which the parasite utilizes a critical cysteine protease from the papain family. Examples of parasitic diseases to be treated or prevented by the compounds of the invention include, but are not limited to, toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, leishmaniasis, coccidiosis, giardiosis, cryptosporidiosis or schistosomiasis.
    Type: Application
    Filed: June 16, 2010
    Publication date: April 26, 2012
    Inventors: Cameron Black, Christian Beaulieu
  • Publication number: 20120100124
    Abstract: The invention relates to methods for detecting the oncogenic condition of cells, including step where the amount of the OCDO compound in said cells is measured, and to the uses thereof. The invention further relates to OCDO inhibitors for use in methods for treating cancer.
    Type: Application
    Filed: June 25, 2010
    Publication date: April 26, 2012
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), AFFICHEM
    Inventors: Philippe De Medina, Michaél Paillasse, Marc Poirot, Sandrine Silvente-Poirot
  • Publication number: 20120095019
    Abstract: This invention is directed to methods of inhibiting coagulation or treating thrombosis using a factor Xa inhibitor and a P-glycoprotein (Pgp) inhibitor. The invention is also directed to formulations used in the methods.
    Type: Application
    Filed: August 31, 2011
    Publication date: April 19, 2012
    Inventors: Uma Sinha, George A. Mansoor, Anne Hermanowski Vosatka, Vincent R. Capodanno, Robert M. Wenslow, Richard G. Ball, Eric L. Margelefsky, Timothy K. Maher, Itzia Zoraida Arroyo, Brett Lauring, Liam Corcoran, William Denney, Michael McNevin, Anjali Pandey
  • Publication number: 20120095006
    Abstract: This invention relates to the use of certain cyclic guanosine 3?,5?-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of pulmonary hypertension.
    Type: Application
    Filed: December 16, 2011
    Publication date: April 19, 2012
    Inventors: Ghazwan Saleem Butrous, Timothy Michael Lukas, Ian Machin
  • Patent number: 8148367
    Abstract: Disclosed are compounds, pharmaceutical compositions, kits, articles of manufacture, methods of using, and methods of preparing compounds having the formula: wherein the variables are as defined herein. The disclosed compounds are inhibitors of Renin.
    Type: Grant
    Filed: January 9, 2008
    Date of Patent: April 3, 2012
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Lily Kwok, Betty Lam, Zhe Li, Zhiyuan Zhang
  • Publication number: 20120077822
    Abstract: An in situ film-forming sprayable methyl acetate-based solution of at least one absorbable, low-crystallinity, segmented copolymer contains at least one bioactive agent, which exhibits antimicrobial, anti-inflammatory, antiviral, anesthetic, hemostatic, and/or antineoplastic activity. The absorbable polymers can be a polyaxial copolyester, polyether-ester and polyether-ester urethane and the bioactive solution thereof can be applied onto animal and human skin or accessible body cavities to prevent or treat one or more disorder susceptible to the bioactive agent therein.
    Type: Application
    Filed: January 29, 2011
    Publication date: March 29, 2012
    Inventors: Shalaby W. Shalaby, Joel T. Corbett, Jason Olbrich
  • Publication number: 20120077824
    Abstract: Provided herein is a pharmaceutical injectable formulation of itraconazole (10 mg/g) where the formulation comprises a solubilizer, a nonionic surfactant/emulsifier, a co-surfactant and a stabilizer. Further provided is a pharmaceutical formulation of itraconazole, said formulation comprising a solubilizer in a concentration of from about 20% to about 75%, a nonionic surfactant/emulsifier in a concentration of from about 20% to about 50%, a co-surfactant in a concentration from about 10% to about 45% and a stabilizer in a concentration of from about 1% to about 15%.
    Type: Application
    Filed: September 22, 2011
    Publication date: March 29, 2012
    Inventors: Dong Liang, Lei Wu, Mathew Kizhakkekara Joseph, Jyothy Anie John
  • Publication number: 20120077767
    Abstract: Methods for identifying fungal infection, assays for identifying genomic and protein markers of fungal infection, and methods for diagnosing the fungal infection. In one aspect, the method of identifying fungal infection by proteomic assay involves measuring the protein levels of proteins listed in Table 2A in a peripheral blood cell sample and comparing the determined protein levels to standard protein levels. In another aspect, subjects identified as being infected with fungal infection are treated with anti-fungals.
    Type: Application
    Filed: May 26, 2010
    Publication date: March 29, 2012
    Inventors: Aimee K. Zaas, Geoffrey S. Ginsburg, Joseph Lucas, Hamza Aziz, John R. Perfect
  • Publication number: 20120077823
    Abstract: Controlled release systems release at least one pluribioactive antifungal drug exhibiting at least one additional bioactivity from the group consisting of spermiostatic, antineoplastic, antibacterial, antirestenotic and antiviral activities. The drug release system is designed for use as a spermiostatic contraceptive, intravaginal ringed-mesh which may also exhibit antiviral activity, an in situ-forming implant for treating different forms of cancer and topical film for treating or preventing bacterial and fungal infections.
    Type: Application
    Filed: January 29, 2011
    Publication date: March 29, 2012
    Inventors: Shalaby W. Shalaby, Georgios T. Hilas, Sheila Nagatomi
  • Publication number: 20120071456
    Abstract: Hair treatment composition comprising a zinc-based antidandruff agent, a conazole fungicide and a cationic modified guar deposition polymer.
    Type: Application
    Filed: April 12, 2010
    Publication date: March 22, 2012
    Inventors: Wanlin Chang, Amit Jayaswal, Zheng Rong Li, Busaraporn Samran
  • Publication number: 20120070384
    Abstract: A topical, foamable composition is provided that includes at least one antifungal agent that is able to penetrate the upper layers of skin and is retained in or on an area to be treated for a prolonged period of time, and that has a residual non-volatile component content less than 25%. In addition, a method of treating fungal diseases including jock itch, tinea, dandruff and sebborheic dermatitis is provided, and includes applying to the affected area of patient requiring such treatment an antifungal composition.
    Type: Application
    Filed: June 21, 2011
    Publication date: March 22, 2012
    Applicant: STIEFEL RESEARCH AUSTRALIA PTY LTD
    Inventors: Greg DAVEY, Albert Zorko ABRAM
  • Publication number: 20120058199
    Abstract: The present invention provides the use of surface active proteins, especially class I and class II hydrophobins, in topically applied pharmaceutical formulations. The invention is particularly directed to topically applied pharmaceutical products for enhancing the penetration to achieve a transungual delivery of a prophylactically and/or therapeutically effective amount of an active ingredient (drug) to a patient (including animals and humans) into and/or through a nail, of the animal or human body, in order to treat one or more of a variety of diseases or disorders. Related embodiments of the invention are also disclosed.
    Type: Application
    Filed: February 19, 2010
    Publication date: March 8, 2012
    Applicant: BASF SE
    Inventors: Andreas Buthe, Andreas Hafner, Franz Kaufmann, Babette Fiedler, Guido Meurer, Gordon Bradley
  • Publication number: 20120052130
    Abstract: Compounds of Formula (I) that modulate the activity of the G-protein-coupled receptor GPFM 19 and their uses in the treatment of diseases linked to the modulation of the G-protein-coupled receptor GPR119 in animals are described herein.
    Type: Application
    Filed: April 12, 2010
    Publication date: March 1, 2012
    Inventors: Etzer Darout, Michael Paul DeNinno, Kentaro Futatsugi, Cristiano Ruch Werneck Guimaraes, Bruce Allen Lefker, Vincent Mascitti, Kim Francis McClure, Michael John Munchhof, Ralph Pelton Robinson, JR.
  • Publication number: 20120053139
    Abstract: The present invention provides methods for improving the pharmacokinetics of protease inhibitors and protease inhibitor precursors and pharmaceutical composition comprising protease inhibitors or protease inhibitor precursors of formula I and a cytochrome P450 monooxigenase inhibitor; when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein R1 may be, for example, (HO)2P(O)—, (NaO)2P(O)—, alkyl-CO— or cycloalkyl-CO—, wherein X may be, for example, F, Cl, and Br, and wherein R2 and R3 are as defined herein.
    Type: Application
    Filed: August 24, 2011
    Publication date: March 1, 2012
    Applicant: Ambrilia Biopharma Inc.
    Inventors: Jinzi Jason Wu, Brent Richard Stranix, Michael Ge, Guy Milot, Marco Petrella, Chandra J. Panchal
  • Publication number: 20120040995
    Abstract: Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed that have lower neurotoxicity effects than other compounds.
    Type: Application
    Filed: February 9, 2010
    Publication date: February 16, 2012
    Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Paul J. Hergenrother, Quinn Patrick Peterson, Danny Chung Hsu, Diana C. West, Timothy M. Fan, Chris J. Novotny
  • Publication number: 20120035186
    Abstract: Hair treatment composition comprising an azole fungicide and zinc gluconate and wherein the composition does not comprise Trichogen®.
    Type: Application
    Filed: April 13, 2010
    Publication date: February 9, 2012
    Inventors: Jason Shaun Burry, Richard Livesey Evans, Graham Andrew Turner
  • Publication number: 20120028920
    Abstract: A heterocyclic compound or a salt thereof represented by the formula (1): where R2 represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or lower alkenylene group; and R1 represents an aromatic group or a heterocyclic group. The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.
    Type: Application
    Filed: October 11, 2011
    Publication date: February 2, 2012
    Inventors: Hiroshi YAMASHITA, Hideaki Kuroda, Nobuaki Ito, Shin Miyamura, Kunio Oshima, Jun Matsubara, Haruka Takahashi, Tae Fukushima, Satoshi Shimizu, Kazumi Kondo, Yohji Sakurai, Takeshi Kuroda, Shinichi Taira, Motohiro Itotani, Tatsuyoshi Tanaka
  • Publication number: 20120022079
    Abstract: The invention relates to a process for producing formulations of sparingly water-soluble substances, said sparingly soluble substances being present in amorphous embedded form in a copolymer, and said copolymer being obtained by free-radically initiated polymerization of a mixture of i) 30 to 80% by weight of N-vinyllactam, ii) 10 to 50% by weight of vinyl acetate, and iii) 10 to 50% by weight of a polyether, with the proviso that the sum of components i), ii) and iii) equals 100% by weight, which comprises embedding the sparingly soluble substance into the copolymer at temperatures above the melting point of the sparingly soluble substances.
    Type: Application
    Filed: March 30, 2010
    Publication date: January 26, 2012
    Applicant: BASF SE
    Inventors: Kathrin Meyer-Böehm, Rainer Dobrawa, Stefan Fischer, Karl Kolter
  • Publication number: 20120022021
    Abstract: The present invention relates to mixtures comprising a) a compound of the formula I in which X, m, Q and a are as defined in the description and b) one or more ethylene modulators (II) selected from the group consisting of: inhibitors of ethylene biosynthesis which inhibit the conversion of S-adenosyl-L-methionine into 1-aminocyclopropane-1-carboxylic acid (ACC), inhibitors of ethylene biosynthesis which block the conversion of ACC into ethylene, or inhibitors of ethylene action, and also to compositions comprising them and to their use for controlling harmful fungi.
    Type: Application
    Filed: September 28, 2011
    Publication date: January 26, 2012
    Applicant: BASF SE
    Inventors: Wilhelm RADEMACHER, John S. HARDEN, Dan E. WESTBERG, Joseph E. ZAWIERUCHA, Thomas J. HOLT, Hendrik YPEMA, Ted R. BARDINELLI, Albert C. EVERSON, Edson BEGLIOMINI
  • Publication number: 20120010161
    Abstract: The present invention relates to compounds of azapeptide or azapeptidomimetic type of formula (I): in which R1, R2, R3, X1, X2, X3, X4 and Y are as defined in claim 1, to pharmaceutical compositions containing them and to such compounds as adjuvant for an anticancer or anti-infectious medicament.
    Type: Application
    Filed: January 25, 2010
    Publication date: January 12, 2012
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE CLAUDE BERNARD LYON I
    Inventor: Joelle Paris
  • Publication number: 20120003306
    Abstract: The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
    Type: Application
    Filed: September 8, 2011
    Publication date: January 5, 2012
    Inventors: Hsing-Wen Sung, Kiran Sonaje, Hosheng Tu
  • Patent number: 8084445
    Abstract: Disclosed are novel formulations for the treatment of otic infections in an animal comprising a triazole anti-fungal compound, a quinolone antibiotic and a corticosteroid such as mometasone furoate monohydrate.
    Type: Grant
    Filed: August 10, 2005
    Date of Patent: December 27, 2011
    Assignee: Schering-Plough Animal Health Corporation
    Inventors: Abu S Huq, Allan J Weingarten, Robert D Simmons
  • Publication number: 20110311545
    Abstract: A method may include treating pain, shock, and/or inflammatory conditions in a subject. A method may include using a therapeutically effective amount of an antibody, a lipoxygenase inhibitor, a cytochrome P-450 enzyme inhibitor, and/or an antioxidant configurable to at least partially treat pain, shock, and/or inflammatory conditions in a subject. A method of treating pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation).
    Type: Application
    Filed: November 24, 2009
    Publication date: December 22, 2011
    Inventors: Amol Madhusudan Patwardhan, Kenneth Michael Hargreaves, Armen Norakovich Akopian
  • Publication number: 20110312931
    Abstract: The compounds of the present invention are represented by the following formula (I): wherein the substituents R1, R2, R3, R4, (R5)m, R6, A, X, and Y are as defined herein. The compounds are useful in methods of treating a disorder which is created by or is dependent upon inhibiting GlyT-1.
    Type: Application
    Filed: June 2, 2011
    Publication date: December 22, 2011
    Applicant: ALBANY MOLECULAR RESEARCH, INC.
    Inventors: Christopher L. CIOFFI, Mark A. WOLF, Peter R. GUZZO, Shuang LIU, Kashinath SADALAPURE, Visweswaran PARTHASARATHY, Jun-Ho MAENG
  • Publication number: 20110300104
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the Hepatitis C Virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the Hepatitis C Virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: June 3, 2011
    Publication date: December 8, 2011
    Inventors: Yao-Ling Qiu, Ce Wang, Hui Cao, Xiaowen Peng, Datong Tang, Yat Sun Or
  • Publication number: 20110301099
    Abstract: A method and composition that allows for the penetration of lipid insoluble medicaments through cell membranes using small S-Allyl-containing molecules with phospholipid permeable molecules as carrier molecules. S-Allyl-containing compounds can include alliin, allicin, Allium sativum extract and DMSO. Lipid insoluble medicaments can include 1% xylocaine, curcumin, acyclovir, valacyclovir, famciclovir, terbenafin, griseofulvin, clotrimazole, ketoconazole, clindamycin, neomycin, polysporin, bactricin, among others. The lipid insoluble medicaments are mixed with the phospholipid permeable molecules and painted on the skin using a swab or other suitable tool, thereby allowing for penetration of the medicament and providing relief from pain potentially caused by a subsequent injection. The composition can also be administered through an inhaler or directly into mucous membranes.
    Type: Application
    Filed: June 4, 2010
    Publication date: December 8, 2011
    Inventor: Madalene Choon Ying Heng
  • Publication number: 20110287066
    Abstract: Process for the production of nanoporous foamed active substance-containing preparations, wherein the active substance is present embedded in a pharmaceutically acceptable polymer, wherein, in stage a) loading of a polymeric molding composition or a polymer melt with a propellant is effected at a pressure and at a temperature at which the propellant is in the supercritical state, in stage b) heating of the laden polymer molding compound or melt is carried out under pressure at a temperature which lies in the range from ?40 to +60° C., preferably ?20 to +55° C., and especially preferably 0 to +50° C. around the glass transition temperature of the unladen (prior to loading) polymeric molding compound and in stage c) a depressurization of the polymeric molding compound or melt laden in stage a) and heated under pressure in stage b) is effected out with a depressurization rate in the range from 15,000 to 200,000 MPa/sec.
    Type: Application
    Filed: May 20, 2011
    Publication date: November 24, 2011
    Applicant: BASF SE
    Inventors: Jan Kurt Walter Sandler, Ingo Bellin, Dejan Djuric, Karl Kolter, Holger Ruckdäschel
  • Publication number: 20110281810
    Abstract: The present invention relates to the use of a solubilizer for enhancing the solubility of an active pharmaceutical ingredient in water. The present invention further relates to a composition comprising a solubilizer and at least one active pharmaceutical ingredient. In both cases the solubilizer is an alkoxylated monoalcohol or a mixture of alkoxylated monoalcohols, where the alkoxylated monoalcohol or, if a mixture of alkoxylated monoalcohols is present, at least one alkoxylated monoalcohol in the mixture comprises at least one oxypropylene unit.
    Type: Application
    Filed: April 13, 2011
    Publication date: November 17, 2011
    Applicant: Cognis IP Management GmbH
    Inventors: Kirsten Petersen, Bernd W. Müller, Thomas Rosen
  • Publication number: 20110274651
    Abstract: Compositions and methods for treating or preventing infectious diseases, and inhibiting the ability of microbes to travel within mammalian cells, and inhibiting microbial replication, are disclosed. The compositions include various noscapine analogs, which are capable of blocking the movement of viruses and other microbes within mammalian and other cells by inhibiting the cytoplasmic transport mechanisms within the cells. The compositions described herein include an effective amount of the noscapine analogues described herein, along with a pharmaceutically acceptable carrier or excipient. The compositions can also include one or more additional antimicrobial compounds.
    Type: Application
    Filed: September 4, 2009
    Publication date: November 10, 2011
    Applicant: Emory University
    Inventors: Cory Acuff, Daniel Kalman
  • Publication number: 20110275558
    Abstract: The present invention relates to the field of medical treatments for diseases and disorders. More specifically, the present invention relates to the use of the lanthionine synthetase component C-like (LANCL) proteins as therapeutic targets for novel classes of anti-inflammatory, immune regulatory and antidiabetic drugs.
    Type: Application
    Filed: May 4, 2011
    Publication date: November 10, 2011
    Applicant: Virginia Tech Intellectual Properties, Inc.
    Inventors: Josep BASSAGANYA-RIERA, Pinyi LU, Raquel HONTECILLAS
  • Publication number: 20110269768
    Abstract: This invention is directed to a compound of Formula (I): and forms thereof, wherein A, B, E, G, X and L2 are as defined herein and their use as urotensin II receptor antagonists.
    Type: Application
    Filed: July 14, 2011
    Publication date: November 3, 2011
    Inventors: William A. Kinney, Edward C. Lawson, Shyamali Ghosh, Diane K. Luci, David F. McComsey
  • Publication number: 20110262517
    Abstract: Described herein are methods of inhibiting angiogenesis, and treating or preventing a disease or disorder (or symptoms thereof) associated with angiogenesis, wherein an anti-angiogenesis compound is administered to a subject.
    Type: Application
    Filed: April 7, 2008
    Publication date: October 27, 2011
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Jun O. Liu, Curtis R. Chong, Jing Xu, Jun Lu, Shridhar Bhat
  • Publication number: 20110244028
    Abstract: The invention describes a method of preparing lipid compositions by associating pH sensitive compounds which maybe weak acids, bases or amphoteric compounds with at least one ionisable or pH sensitive group and low water solubility into preformed and standardised lipid particles by pH manipulation. Drug association is carried out in situ by changing the pH of the aqueous medium to pH 6-8 wherein the compound spontaneously partitions into the lipid particles. Drug association may also be carried out by exploiting pH changes in the GI tract. The lipophilic compound is solubilised by the lipid particles and may be used as such for in-vitro and pharmacokinetic assessments or processed for oral, parenteral or topical therapy.
    Type: Application
    Filed: September 28, 2009
    Publication date: October 6, 2011
    Inventors: Steve Leigh, Mathew Leuis Steven Leigh, Peter Van Hoogevest
  • Publication number: 20110244004
    Abstract: A liquid suspension comprising an antifungally effective amount of the micronized compound represented by the chemical structural formula I: at least one thickening agent, a non-ionic surfactant, and a pharmaceutically acceptable liquid carrier is disclosed.
    Type: Application
    Filed: June 15, 2011
    Publication date: October 6, 2011
    Applicant: Schering-Plough Corporation
    Inventors: Stefan Sharpe, Joel Sequeira, David Harris, Shashank Mahashabde
  • Publication number: 20110237603
    Abstract: The present invention is directed to solvates and various polymorphic forms of (E)-1-[[[5-(4-chlorophenyl)-2-furanyl]methylene]amino]-3-[4-(4-methyl-1-piperazinyl)butyl]-2,4-imidazolidinedione dihydrochloride and pharmaceutical compositions thereof.
    Type: Application
    Filed: June 9, 2011
    Publication date: September 29, 2011
    Applicant: WARNER CHILCOTT COMPANY, LLC
    Inventor: Nancy Lee REDMAN-FUREY
  • Publication number: 20110224141
    Abstract: A method of treatment and/or prevention of cancer comprises administering agents which cause increased intracellular granularity in cancer cells, at least in an amount sufficient to inhibit proliferation of such cells and preferably in an amount sufficient to lead to cancer cell death. The method is particularly directed to refractory cancer, particularly hormone refractory prostate cancer. The agents identified cause increased intracellular granularity in the cancer cells, and also convert adherent cancer cells to non-adherent cancer cells, leading to cancer cell death. Using the present invention, cancer cells undergo increased intracellular granularity at relatively low agent concentrations, while also inhibiting cell proliferation. Increased concentrations lead to conversion of adherent cancer cells to non-adherent cancer cells, then to cell death.
    Type: Application
    Filed: June 5, 2009
    Publication date: September 15, 2011
    Applicant: STC.UNM
    Inventors: Todd A. Thompson, Debra Mackenzie, Tudor I. Oprea, Larry A. Sklar, Bruce S. Edwards, Mark Haynes
  • Publication number: 20110224723
    Abstract: A tissue adhesive including cyanoacrylate and polyethylene glycol (PEG), wherein the PEG remains a polyether and wherein the tissue adhesive is bioabsorbable. A tissue adhesive including cyanoacrylate bulk monomer and cyanoacrylate nanoparticles containing a therapeutic therein. A kit for applying a tissue adhesive, including the tissue adhesive described above and an applicator. Methods of accelerating degradation of a cyanoacrylate tissue adhesive applying a tissue adhesive, closing an internal wound, administering a therapeutic to tissue, treating cancer, and preventing infection in a wound. Methods of method of making a bioabsorbable tissue adhesive and making a therapeutic tissue adhesive.
    Type: Application
    Filed: November 14, 2007
    Publication date: September 15, 2011
    Inventors: Jeoung Soo Lee, Charles Kenneth Webb, Robert Ziummerman, Rafael Ruiz, SR.
  • Publication number: 20110224179
    Abstract: We disclose a diagnostic test to determine suitable therapeutic intervention of subjects suffering from subclinical Cushing's syndrome [SCS] and also agents that antagonise the action of cortisol or inhibit excess cortisol production in the treatment of conditions such as SCS in the presence of an adrenal incidentaloma.
    Type: Application
    Filed: November 7, 2008
    Publication date: September 15, 2011
    Inventor: John Newell-Price
  • Publication number: 20110224228
    Abstract: Novel derivatives of enfumafungin are disclosed herein, along with' their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and method of using such compounds as antifungal agents and/or inhibitors of (1,3)-?-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions.
    Type: Application
    Filed: August 10, 2009
    Publication date: September 15, 2011
    Applicants: Merck Sharp & Dohme Corp., Scynexis, Inc.
    Inventors: Mark L Greenlee, Robert Wilkening, James Apgar, Donald Sperbeck, Kenneth J. Wildonger, Dongfang Meng, Dann L. Parker, JR., Ahmed Mamai
  • Publication number: 20110218166
    Abstract: The present invention has as its objective to provide mucoadherent compositions with enhanced properties of bioadhesivity, consistency, stability and vaginal pH regulation. It can also be the carrier of an active principle for the treatment or prophylaxis of disturbances or diseases caused in mucosa, particularly in the vaginal tract, as well as their use.
    Type: Application
    Filed: August 14, 2009
    Publication date: September 8, 2011
    Applicant: Incrementha PD&I - Pesquisa, Desenvolvimento e Inovecao de Famacos e Medicamentos Ltda.
    Inventors: Haline Fernanda Santana Castanho, Lupércio Calefe